Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1992 Jun;60(6):2506–2513. doi: 10.1128/iai.60.6.2506-2513.1992

Binding and neutralization of endotoxin by Limulus antilipopolysaccharide factor.

H S Warren 1, M L Glennon 1, N Wainwright 1, S F Amato 1, K M Black 1, S J Kirsch 1, G R Riveau 1, R I Whyte 1, W M Zapol 1, T J Novitsky 1
PMCID: PMC257189  PMID: 1587618

Abstract

In order to examine the ability of Limulus antilipopolysaccharide factor (LALF) to bind lipopolysaccharide (LPS), we purified LALF to homogeneity from Limulus amoebocyte lysate and coupled it covalently to agarose beads. LALF-coupled beads captured more tritiated LPS from rough and smooth strains of gram-negative bacteria than did control human serum albumin-coupled beads. Unlabeled homologous and heterologous LPS competed for the binding of 3H-LPS to LALF-coupled beads. LALF bound LPS in a dose-dependent manner as assessed by the precipitation of LPS-LALF complexes with 50% saturated ammonium sulfate. We also studied the ability of LALF to neutralize LPS. LPS preincubated with LALF was less mitogenic for murine splenocytes, was less pyrogenic in the rabbit fever assay, was less lethal in mice which had been sensitized to LPS with actinomycin D, and induced less fever, neutropenia, and pulmonary hypertension when infused into sheep. Our findings extend prior studies which suggested that LALF binds to and neutralizes LPS from multiple strains of gram-negative bacteria.

Full text

PDF
2506

Images in this article

2507Image
on p.2507

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aketagawa J., Miyata T., Ohtsubo S., Nakamura T., Morita T., Hayashida H., Miyata T., Iwanaga S., Takao T., Shimonishi Y. Primary structure of limulus anticoagulant anti-lipopolysaccharide factor. J Biol Chem. 1986 Jun 5;261(16):7357–7365. [PubMed] [Google Scholar]
  2. Alpert G., Baldwin G., Thompson C., Wainwright N., Novitsky T. J., Gillis Z., Parsonnet J., Fleisher G. R., Siber G. R. Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock. J Infect Dis. 1992 Mar;165(3):494–500. doi: 10.1093/infdis/165.3.494. [DOI] [PubMed] [Google Scholar]
  3. Bannatyne R. M., Cheung R. Protective effect of polymyxin B sulfate in experimental enterobacterial infection in mice. Can J Microbiol. 1979 Sep;25(9):995–998. doi: 10.1139/m79-153. [DOI] [PubMed] [Google Scholar]
  4. Brown D. E., Morrison D. C. Possible alteration of normal mechanisms of endotoxin toxicity in vivo by actinomycin D. J Infect Dis. 1982 Dec;146(6):746–750. doi: 10.1093/infdis/146.6.746. [DOI] [PubMed] [Google Scholar]
  5. Chedid L., Parant M., Parant F., Boyer F. A proposed mechanism for natural immunity to enterobacterial pathogens. J Immunol. 1968 Feb;100(2):292–306. [PubMed] [Google Scholar]
  6. Colwell D. E., Michalek S. M., Briles D. E., Jirillo E., McGhee J. R. Monoclonal antibodies to Salmonella lipopolysaccharide: anti-O-polysaccharide antibodies protect C3H mice against challenge with virulent Salmonella typhimurium. J Immunol. 1984 Aug;133(2):950–957. [PubMed] [Google Scholar]
  7. Corrigan J. J., Jr, Bell B. M. Endotoxin-induced intravascular coagulation: prevention with polymyxin B sulfate. J Lab Clin Med. 1971 May;77(5):802–810. [PubMed] [Google Scholar]
  8. Corrigan J. J., Jr, Kiernat J. F. Effect of polymyxin B sulfate on endotoxin activity in a gram-negative septicemia model. Pediatr Res. 1979 Jan;13(1):48–51. doi: 10.1203/00006450-197901000-00011. [DOI] [PubMed] [Google Scholar]
  9. Coughlin R. T., Bogard W. C., Jr Immunoprotective murine monoclonal antibodies specific for the outer-core polysaccharide and for the O-antigen of Escherichia coli 0111:B4 lipopolysaccharide (LPS). J Immunol. 1987 Jul 15;139(2):557–561. [PubMed] [Google Scholar]
  10. Desch C. E., O'Hara P., Harlan J. M. Antilipopolysaccharide factor from horseshoe crab, Tachypleus tridentatus, inhibits lipopolysaccharide activation of cultured human endothelial cells. Infect Immun. 1989 May;57(5):1612–1614. doi: 10.1128/iai.57.5.1612-1614.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. FARR R. S. A quantitative immunochemical measure of the primary interaction between I BSA and antibody. J Infect Dis. 1958 Nov-Dec;103(3):239–262. doi: 10.1093/infdis/103.3.239. [DOI] [PubMed] [Google Scholar]
  12. Galanos C., Lüderitz O., Westphal O. A new method for the extraction of R lipopolysaccharides. Eur J Biochem. 1969 Jun;9(2):245–249. doi: 10.1111/j.1432-1033.1969.tb00601.x. [DOI] [PubMed] [Google Scholar]
  13. Greenman R. L., Schein R. M., Martin M. A., Wenzel R. P., MacIntyre N. R., Emmanuel G., Chmel H., Kohler R. B., McCarthy M., Plouffe J. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA. 1991 Aug 28;266(8):1097–1102. [PubMed] [Google Scholar]
  14. Greisman S. E., Young E. J., DuBuy B. Mechanisms of endotoxin tolerance. 8. Specificity of serum transfer. J Immunol. 1973 Nov;111(5):1349–1360. [PubMed] [Google Scholar]
  15. Jacobs M. D., Morrison D. C. Dissociation between mitogenicity and immunogenicity of TNP-lipopolysaccharide, a T-independent antigen. J Exp Med. 1975 Jun 1;141(6):1453–1458. doi: 10.1084/jem.141.6.1453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Johns M., Skehill A., McCabe W. R. Immunization with rough mutants of Salmonella minnesota. IV. Protection by antisera to O and rough antigens against endotoxin. J Infect Dis. 1983 Jan;147(1):57–67. doi: 10.1093/infdis/147.1.57. [DOI] [PubMed] [Google Scholar]
  17. Kirkland T. N., Ziegler E. J. An immunoprotective monoclonal antibody to lipopolysaccharide. J Immunol. 1984 May;132(5):2590–2592. [PubMed] [Google Scholar]
  18. Marra M. N., Wilde C. G., Griffith J. E., Snable J. L., Scott R. W. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J Immunol. 1990 Jan 15;144(2):662–666. [PubMed] [Google Scholar]
  19. McCabe W. R. Immunization with R mutants of S. Minnesota. I. Protection against challenge with heterologous gram-negative bacilli. J Immunol. 1972 Mar;108(3):601–610. [PubMed] [Google Scholar]
  20. Montaraz J. A., Winter A. J., Hunter D. M., Sowa B. A., Wu A. M., Adams L. G. Protection against Brucella abortus in mice with O-polysaccharide-specific monoclonal antibodies. Infect Immun. 1986 Mar;51(3):961–963. doi: 10.1128/iai.51.3.961-963.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Morita T., Ohtsubo S., Nakamura T., Tanaka S., Iwanaga S., Ohashi K., Niwa M. Isolation and biological activities of limulus anticoagulant (anti-LPS factor) which interacts with lipopolysaccharide (LPS). J Biochem. 1985 Jun;97(6):1611–1620. doi: 10.1093/oxfordjournals.jbchem.a135218. [DOI] [PubMed] [Google Scholar]
  22. Munford R. S., Hall C. L., Dietschy J. M. Binding of Salmonella typhimurium lipopolysaccharides to rat high-density lipoproteins. Infect Immun. 1981 Dec;34(3):835–843. doi: 10.1128/iai.34.3.835-843.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Munford R. S., Hall C. L., Lipton J. M., Dietschy J. M. Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides. J Clin Invest. 1982 Oct;70(4):877–888. doi: 10.1172/JCI110684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Munford R. S., Hall C. L. Radioimmunoassay for Gram-negative bacterial lipopolysaccharide O antigens: influence of antigen solubility. Infect Immun. 1979 Oct;26(1):42–48. doi: 10.1128/iai.26.1.42-48.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Muta T., Miyata T., Tokunaga F., Nakamura T., Iwanaga S. Primary structure of anti-lipopolysaccharide factor from American horseshoe crab, Limulus polyphemus. J Biochem. 1987 Jun;101(6):1321–1330. doi: 10.1093/oxfordjournals.jbchem.a121999. [DOI] [PubMed] [Google Scholar]
  26. Novitsky T. J., Roslansky P. F., Siber G. R., Warren H. S. Turbidimetric method for quantifying serum inhibition of Limulus amoebocyte lysate. J Clin Microbiol. 1985 Feb;21(2):211–216. doi: 10.1128/jcm.21.2.211-216.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. OSBORN M. J., ROSEN S. M., ROTHFIELD L., HORECKER B. L. Biosynthesis of bacterial lipopolysaccharide. I. Enzymatic incorporation of galactose in a mutant strain of Salmonella. Proc Natl Acad Sci U S A. 1962 Oct 15;48:1831–1838. doi: 10.1073/pnas.48.10.1831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Ohashi K., Niwa M., Nakamura T., Morita T., Iwanaga S. Anti-LPS factor in the horseshoe crab, Tachypleus tridentatus. Its hemolytic activity on the red blood cell sensitized with lipopolysaccharide. FEBS Lett. 1984 Oct 15;176(1):207–210. doi: 10.1016/0014-5793(84)80942-4. [DOI] [PubMed] [Google Scholar]
  29. Palmer J. D., Rifkind D. Neutralization of the hemodynamic effects of endotoxin by polymyxin B. Surg Gynecol Obstet. 1974 May;138(5):755–759. [PubMed] [Google Scholar]
  30. Pieroni R. E., Broderick E. J., Bundeally A., Levine L. A simple method for the quantitation of submicrogram amounts of bacterial endotoxin. Proc Soc Exp Biol Med. 1970 Mar;133(3):790–794. doi: 10.3181/00379727-133-34565. [DOI] [PubMed] [Google Scholar]
  31. Rifkind D., Hill R. B., Jr Neutralization of the Shwartzman reactions by polymyxins B. J Immunol. 1967 Sep;99(3):564–569. [PubMed] [Google Scholar]
  32. Rifkind D., Palmer J. D. Neutralization of endotoxin toxicity in chick embryos by antibiotics. J Bacteriol. 1966 Oct;92(4):815–819. doi: 10.1128/jb.92.4.815-819.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Rifkind D. Prevention by polymyxin B of endotoxin lethality in mice. J Bacteriol. 1967 Apr;93(4):1463–1464. doi: 10.1128/jb.93.4.1463-1464.1967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Riveau G. R., Novitsky T. J., Roslansky P. F., Dinarello C. A., Warren H. S. Role of interleukin-1 in augmenting serum neutralization of bacterial lipopolysaccharide. J Clin Microbiol. 1987 May;25(5):889–892. doi: 10.1128/jcm.25.5.889-892.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Romeo D., Girard A., Rothfield L. Reconstitution of a functional membrane enzyme system in a monomolecular film. I. Formation of a mixed monolayer of lipopolysaccharide and phospholipid. J Mol Biol. 1970 Nov 14;53(3):475–490. doi: 10.1016/0022-2836(70)90078-1. [DOI] [PubMed] [Google Scholar]
  36. Rudbach J. A., Akiya F. I., Elin R. J., Hochstein H. D., Luoma M. K., Milner E. C., Milner K. C., Thomas K. R. Preparation and properties of a national reference endotoxin. J Clin Microbiol. 1976 Jan;3(1):21–25. doi: 10.1128/jcm.3.1.21-25.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Tanaka S., Nakamura T., Morita T., Iwanaga S. Limulus anti-LPS factor: an anticoagulant which inhibits the endotoxin mediated activation of Limulus coagulation system. Biochem Biophys Res Commun. 1982 Mar 30;105(2):717–723. doi: 10.1016/0006-291x(82)91493-0. [DOI] [PubMed] [Google Scholar]
  38. Tate W. J., 3rd, Douglas H., Braude A. I., Wells W. W. Protection against lethality of E. coli endotoxin with "O" antiserum. Ann N Y Acad Sci. 1966 Jun 30;133(2):746–762. doi: 10.1111/j.1749-6632.1966.tb52403.x. [DOI] [PubMed] [Google Scholar]
  39. Ulevitch R. J., Johnston A. R. The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum. J Clin Invest. 1978 Dec;62(6):1313–1324. doi: 10.1172/JCI109252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Warren H. S., Knights C. V., Siber G. R. Neutralization and lipoprotein binding of lipopolysaccharides in tolerant rabbit serum. J Infect Dis. 1986 Nov;154(5):784–791. doi: 10.1093/infdis/154.5.784. [DOI] [PubMed] [Google Scholar]
  41. Weiss J., Elsbach P., Olsson I., Odeberg H. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J Biol Chem. 1978 Apr 25;253(8):2664–2672. [PubMed] [Google Scholar]
  42. Whyte R. I., Warren H. S., Greene E., Glennon M. L., Robinson D. R., Zapol W. M. Tolerance to low-dose endotoxin in awake sheep. J Appl Physiol (1985) 1989 Jun;66(6):2546–2552. doi: 10.1152/jappl.1989.66.6.2546. [DOI] [PubMed] [Google Scholar]
  43. Young L. S., Stevens P., Ingram J. Functional role of antibody against "core" glycolipid of Enterobacteriaceae. J Clin Invest. 1975 Oct;56(4):850–861. doi: 10.1172/JCI108164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Ziegler E. J., Fisher C. J., Jr, Sprung C. L., Straube R. C., Sadoff J. C., Foulke G. E., Wortel C. H., Fink M. P., Dellinger R. P., Teng N. N. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991 Feb 14;324(7):429–436. doi: 10.1056/NEJM199102143240701. [DOI] [PubMed] [Google Scholar]
  45. Ziegler E. J., McCutchan J. A., Fierer J., Glauser M. P., Sadoff J. C., Douglas H., Braude A. I. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med. 1982 Nov 11;307(20):1225–1230. doi: 10.1056/NEJM198211113072001. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES